Study on COVID-19 and blood cancer connection pulled before starting
NCT ID NCT04953312
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study was designed to learn how the protein calprotectin might change blood stem cells in people with severe COVID-19 or certain blood cancers. Researchers planned to compare cells from patients and healthy donors in the lab. However, the study was withdrawn before any participants were enrolled, so no results are available.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC MYELOMONOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Gustave Roussy Institut
Villejuif, 94800, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill keep blood cancer at bay after a stem cell transplant?
- Could muscle loss predict blood cancer outcomes?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Talking about the end: could guided conversations reduce futile cancer treatments?
- Can engineered immune cells outsmart Hard-to-Treat blood cancers?
- Can a Two-Drug combo tame a rare blood cancer?